Hypoactive Sexual Desire Disorder (HSDD) Treatment Market 2019-2027 – Credence Research | Industry Size, Share & Forecast

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Is Expected To Expand At A CAGR of 5.2%

SAN JOSE, United States - August 14, 2019 /MarketersMedia/ —

The latest market report published by Credence Research, Inc. “Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis, 2019- 2027,” the global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

Market Insights

Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self confidence and less connected with their partners. Recent approval of Vyleesi will provide essential momentum for the HSDD market growth. Currently 2 drugs such as BP101 and Prasterone 6.5 mg vaginal insert are under phase 3 clinical trial are being investigated for its safety and efficacy for treatment of HSDD.

Hypoactive sexual desire disorder is the most common type of sexual dysfunction occurring in adult women worldwide manifested by lack of sex interest for a period of six months or more due to personal distress or fluctuating sex hormones during the menstrual cycle. Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy. The PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) aids in initial screening of HSDD. Psychotherapy is suggested to patients showing positive response to counseling sessions with sex therapist.

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

Pharmacotherapy comprises of buspirone and bupropion off label treatment for HSDD in women suffering with low libido associated with anxiety and depression. Testosterone transdermal patches are used as an off label treatment in premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by USFDA for treating HSDD in premenopausal women owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.

North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%. The chief attributing factors responsible for its supreme market growth are growing incidence of low libido in the female population owing to increasing stress in daily life and fluctuating sex hormones during the menstrual cycle. Domicile of key players such as AMAG Pharmaceutcials, Allergan, Plc., S1 Biopharma, Inc. and Sprout Pharmaceuticals, Inc. further propel the market growth in North America regional segment. Europe is placed in the second position with a market share of 32.4% primarily due to affordable reimbursement scenario for the medicines prescribed for the treatment of hypoactive sexual desire disorder (HSDD). Asia Pacific holding a market share of 15.2% will be growing at a rapid pace during the forecast period owing to rising prevalence of HSDD in working women population and developing healthcare infrastructure.

Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceutcials, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc. and Sprout Pharmaceutcials, Inc.

Key Market Movements:

Growing incidence of low sex drive in women population worldwide
Affordable reimbursement scenario for pharmacotherapy employed in the treatment of HSDD
Recent approval of Vyleesi and strong product pipeline will further propel the HSDD market growth during the forecast period

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

TOC:

1. Preface...

2. Executive Summary...

3. Hypoactive Sexual Desire Disorder Treatment Market: Dynamics and Future Outlook...

Chapter 4. Global Hypoactive Sexual Desire Disorder Treatment Market, by Therapy
4.1. Overview
4.2. Buspirone
4.3. Bupropion
4.4. Testosterone
4.5. Flibanserin
4.6. Bremelanotide
4.7. Cognitive Behavior Therapy
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. Prasterone 6.5 mg Vaginal Insert
4.8.1.2. BP101

Chapter 5. Global Hypoactive Sexual Desire Disorder Treatment Market, by Geography
5.1. Overview
5.2. North America Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.2.1. North America Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.2.2. North America Hypoactive Sexual Desire Disorder Treatment Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017– 2027
5.3.1. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.3.2. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.4.1. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific...

Chapter 6. Company Profiles
6.1. AMAG Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Allergan, Plc.
6.3. Ivix LLX
6.4. EndoCeutics, Inc.
6.5. Emotional Brain BV ...

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
Phone: +18003618290
Website: https://www.credenceresearch.com

Source URL: https://marketersmedia.com/hypoactive-sexual-desire-disorder-hsdd-treatment-market-2019-2027-credence-research-industry-size-share-forecast/88908175

Source: MarketersMedia

Release ID: 88908175

Latest News

Australian court upholds sex abuse verdict of Cardinal Pell

Aug 21, 2019

MELBOURNE, Australia — An Australian appeals court Wednesday upheld convictions against Cardinal George Pell, the most senior Catholic to be found guilty of sexually abusing children, in a decision cheered by scores of abuse survivors and victims' advocates demonstrating outside the court. A unanimous jury in December found Pope Francis' former finance minister guilty of molesting two 13-year-old choirboys in Melbourne's St. Patrick's Cathedral more than two decades ago. The Victoria state Court of Appeal rejected his appeal in a 2-1 ruling, with the court's chief justice saying the majority found Pell's accuser to be a compelling "witness of truth."...

Pell's appeal pitted word of former choirboy against priest

Aug 21, 2019

CANBERRA, Australia — Cardinal George Pell's appeal against his convictions for child molestation was largely a question of who the jury should have believed, his accuser or a senior priest whose church role was likened to Pell's bodyguard. Pell's accuser was a 13-year-old choirboy when he alleged that he was abused by then-Melbourne Archbishop Pell at the city's St. Patrick's Cathedral in December 1996 and February 1997. Monsignor Charles Portelli was a master of ceremonies at the 11 a.m. Sunday Masses where the choir sang. A chorister in the 1990s, David Dearing, told police that Portelli, Pell's right-hand man, was...

Scientists say monster penguin once swam New Zealand oceans

Aug 21, 2019

WELLINGTON, New Zealand — Scientists in New Zealand said Wednesday they've found fossilized bones from an extinct monster penguin that was about the size of an adult human and swam the oceans some 60 million years ago. They said the previously undiscovered species is believed to have stood about 1.6 meters (5 feet 2 inches) tall and weighed up to 80 kilograms (176 pounds). It's believed to have been one of several species of giant penguins that thrived soon after dinosaurs died out. The findings were published this week in "Alcheringa: An Australasian Journal of Palaeontology." Paul Scofield, a co-author...

Alleged Christchurch gunman sends letter from prison cell

Aug 21, 2019

WELLINGTON, New Zealand — New Zealand officials admitted Wednesday that they made a mistake by allowing the man accused of killing 51 people at two Christchurch mosques to send a hand-written letter from his prison cell. The six-page letter from Brenton Tarrant was posted this week on the website 4chan, which has become notorious as a place for white supremacists to post their views. And it comes at a sensitive time, with other alleged killers from El Paso to Norway citing Tarrant as an inspiration. The letter appears to be written in pencil on a small notepad and is addressed...

Hundreds of refugees protest outside Australian Parliament

Aug 21, 2019

CANBERRA, Australia — Hundreds of protesters rallied outside Australia's Parliament House on Monday, saying they wanted to highlight the uncertain futures of many refugees since the government replaced permanent protection visas with temporary visas. The protesters were from Iraq, Iran, Sri Lanka, Sudan, Somalia and included Rohingya Muslims from Myanmar. Most were in Australia on three-year visas or five-year visas that are available to refugees who agree to live outside the major cities. Such refugees lose their visas if they to return to their homelands to visit family. "The circumstances of the temporary visas are onerous as well as a...

Stock Markets

About Us

The Morning Herald is a fast news provider in the United States since 2005. Fiercely independent and armed with irreverent intelligence, there’s no other place to get your news other than The Morning Herald.

Contact us: sales[at]themorningherald.com

Subscribe Now!